For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
Prospective, Interventional Pilot Study Of Mobile Devices And Digital Applications To Detect Early Pneumonitis And Other Pulmonary Adverse Events In Unresectable Stage Iii Non-Small Cell Lung Cancer Patients On Durvalumab
To test new technology that monitors your respiratory function data, oxygen saturation levels, vital signs, and physical movement data without affecting your daily life in a significant way.
DiagnosisPatients have unresectable Stage III non-small cell lung cancer and your doctor has prescribed durvalumab as treatment.
Unresectable Stage III NSCLC
No progression post platinum based chemo/radiation
Must be eligible for durvalumab
Cannot be O2 dependence.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Patients will wear a mobile device to collect V/S to help detect early symptoms of pneumonitis during Durvalumab treatment.
Patients will have an introductory Baseline visit, several routine visits needed for your standard cancer treatment, an End-of-Study visit after about 12 months and a follow-up visit 30 days after the End-of-Study visit.
You will use the devices and tablet application to record data at home every day.
For more information, visit ClinicalTrials.gov